# A Study of MD-120 in Patients With Depression

> **NCT04345471** · PHASE3 · COMPLETED · sponsor: **Mochida Pharmaceutical Company, Ltd.** · enrollment: 615 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Desvenlafaxine 100 mg
- **DRUG:** Desvenlafaxine 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04345471
- **Lead sponsor:** Mochida Pharmaceutical Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-18
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-09-14
- **Target enrollment:** 615 (ACTUAL)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345471, "A Study of MD-120 in Patients With Depression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04345471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*